Boron

The VerdictLOW CONVICTIONWorth-It: Poor ROI (32/100)

Every popular boron claim rests on a single small old trial that has never been replicated, a biomarker that does not translate to outcomes, or a rodent meta-analysis that explicitly excluded humans.

Next time you reach for a boron capsule for testosterone, weight loss, or bone health, put it back. Eat an apple, a handful of almonds, and have your coffee. That is what the human evidence actually demonstrates.

Testosterone increase in eugonadal men: WEAK. Naghii 2011 N=8 open-label, 7 days, no placebo. Never replicated in 15 years.
Osteoarthritis symptom relief: WEAK. Newnham 1994 PMID 7889887 N=20 pilot. Never replicated in 30 years. Not in NICE 2022 or OARSI 2019 OA guidelines.
Bone density / fracture: WEAK. Meacham 1994/1995 reduced urinary Ca and Mg excretion. Biomarker only, no BMD or fracture trial.

That's the general answer. Your stack is different.

Check your whole stack

The Protocol

Population	Dose	Timing	Form	Source
Healthy adults (general)	No capsule	n/a	Food: 1 apple, small handful of almonds, 2 cups of coffee	Penland deprivation; IOM DRI
Adult with OA (trial only)	6 mg/d × 8 wk	With a meal	Plain boric acid	Newnham 1994 PMID:7889887 (N=20 pilot, never replicated)
Primary dysmenorrhea (trial only)	10 mg/d × 2 cycles	Daily during cycle	Plain boric acid	Nikkhah 2015 PMID:25906949 (single RCT)
Eugonadal men seeking T boost	Not justified	n/a	n/a	No qualifying placebo-controlled trial exists
Older adults seeking BMD	Not justified	n/a	n/a	No fracture or DXA-confirmed BMD RCT

Forms Comparison

Boric acid

>90% absorbed · £3-6/mo

Trial-replication standard. Used in Naghii 2011, Newnham 1994, Meacham trials. The form to choose if trialing at all.

Sodium tetraborate (borax)

≈ boric acid · £3-5/mo

Cheap, comparable. Form used in Meacham 1994/1995 urinary-mineral trials.

Calcium fructoborate (FB)

No head-to-head PK · £15-30/mo

Premium-form trap. Every outcome trial traces to one industry-affiliated research group. No independent replication of superiority over inorganic boron at matched dose.

Boron glycinate / chelate

No human PK · £10-20/mo

Marketing premium with no head-to-head trial. Boric acid is already >90% absorbed. There is no absorption ceiling for chelation to improve.

Absorption note: Take with a meal to reduce GI discomfort. No co-factor enhances absorption. No documented "absorption trap" — the chelated-form marketing buys nothing measurable.

Safety & Interactions

Tolerable Upper Intake Level: 20 mg/d (IOM US Food and Nutrition Board). 10 mg/d (EFSA Scientific Committee on Food) — the more conservative ceiling. Acute oral toxicity threshold around 4 grams (single dose).

Fluconazole and other azole antifungals (moderate)

Reduced boron clearance reported. Avoid supplementation near the UL while taking azoles; revert to dietary intake only.

HRT, aromatase inhibitors, SERMs (theoretical)

Steroid hormone hydroxylation mechanism is speculative in humans. Discuss with prescriber before any supplementation.

Thiazide diuretics (theoretical)

Additive effect on calcium retention proposed but uncharacterized in human PK studies. Monitor serum calcium if combining.

Contraindicated populations

Pregnancy / lactation above dietary intake — UL drops to 17-20 mg/d. Supplementation above food intake is not supported by efficacy data.
Children — narrower UL ranges, no efficacy evidence.
Severe renal impairment (CKD stage 3+) — boron is renally excreted, accumulation risk.
Hormone-sensitive cancers (ER+ breast, AR+ prostate) — theoretical caution from steroid hormone modulation.

Side effects (chronic above-UL intake)

Seborrheic dermatitis
Alopecia (scalp)
Anorexia, nausea, indigestion, vomiting
Acute toxicity at gram-level doses: CNS depression, blue-green emesis, severe vomiting, dehydration — emergency care

Conviction: LOW

The boron literature is dominated by single small old trials that have never been replicated and biomarker signals that do not translate to clinical outcomes. The most-cited recent meta-analysis (Farrin 2022) is rodents-only by explicit author exclusion. Per-endpoint conviction stratification is detailed below — overall consumer-claim conviction is LOW.

What would change this

An independent (non-industry-affiliated), pre-registered, placebo-controlled, double-blind RCT of ≥150 eugonadal men aged 25–60, 10 mg/d boric acid vs placebo for 12 weeks, total testosterone by LC-MS as primary endpoint, with ≥15% absolute increase over placebo, would upgrade testosterone conviction to MODERATE.
A pre-registered N≥200 placebo-controlled RCT of 6 mg/d boron for 12 weeks in radiographically-confirmed knee OA, WOMAC pain as primary endpoint, would upgrade OA conviction.
A pre-registered N≥300 placebo-controlled fracture-prevention trial in postmenopausal women at 3–6 mg/d over 2 years, morphometric vertebral fracture as primary endpoint, would upgrade bone conviction.
An independent head-to-head pharmacokinetic trial of calcium fructoborate vs boric acid at matched elemental boron dose, with outcome endpoint (not just plasma boron), showing FB superiority, would settle the premium-form question.

Worth Your Money?

Estimated weekly cost

£0.70–£1.50 for plain boric acid at 6 mg/d. £3.50–£7 for calcium fructoborate at matched elemental dose with no documented advantage.

Worth it if

You are trialing a single narrow indication — primary dysmenorrhea or OA — and accept that the underlying evidence is one small trial each, never replicated. Use plain boric acid, stay below the 10 mg/d EFSA UL, reassess at 8–12 weeks.

Lower priority if

Your sleep is short, your training is inconsistent, your protein intake is low, or you have not yet corrected a documented vitamin D deficiency. Those dollars will deliver more than a boron capsule will. Better first dollars include resistance training, adequate protein, and food-first nutrient sufficiency.

Skip — Save Your Money

Sources

Naghii MR et al. (2011) J Trace Elem Med Biol [cite-unverified]. Open-label N=8 men, 10 mg/d × 7 days. Free testosterone increased. No placebo. The single most-cited "boron raises testosterone" reference.
Newnham RE (1994) Environ Health Perspect PMID:7889887. N=20 single-blind RCT, 6 mg/d × 8 wk for OA. Subjective improvement vs placebo. Never replicated.
Meacham SL, Taper LJ, Volpe SL (1994) Environ Health Perspect PMID:7889886. Female athletes, 3 mg/d. Reduced urinary Ca and Mg excretion (biomarker, not BMD/fracture).
Meacham SL, Taper LJ, Volpe SL (1995) J Am Coll Nutr PMID:7840072. Athletic women, urinary boron, blood and urinary Ca/Mg/P.
Penland JG (1994) Environ Health Perspect PMID:7889884. Boron deprivation-rescue, EEG and cognitive performance.
Penland JG (1995) PMID:8861134. Quantitative EEG, combined Mg + B deprivation.
Nikkhah S et al. (2015) Iran J Nurs Midwifery Res PMID:25906949. RCT, 10 mg/d × 2 cycles for primary dysmenorrhea pain.
Farrin N et al. (2022) J Trace Elem Med Biol PMID:35298949. Systematic review + meta-analysis of rodent studies — humans explicitly excluded.
Sahin F et al. (2022) Strahlenther Onkol PMID:34979503. Phase II RCT N=76, TOPICAL boron gel for radiation dermatitis in breast cancer radiotherapy.
Jalali S et al. (2023) Urology PMID:36808295. RCT N=81, boron vs tamsulosin for post-ESWL ureteral stone expulsion (active comparator).
Kuru R et al. (2019) J Trace Elem Med Biol PMID:31109611. Non-randomized self-controlled trial — boron-rich diet, lipids.
Alvarez-Rivera G et al. (2022) Nutrients PMC9409115 [cite-unverified]. Review of boron essentiality and calcium fructoborate clinical landscape.
Nielsen FH, Health Canada (2007) NHP Monograph on Boron [cite-unverified]. Regulatory framing, UL, safety lineage.
IOM Food and Nutrition Board DRI [cite-unverified] — Tolerable Upper Intake 20 mg/d.
EFSA Scientific Committee on Food [cite-unverified] — Tolerable Upper Intake 10 mg/d.

Action ROI

Is this worth your time, money, effort, risk, and trust for this goal? Different from Verdict Score (evidence strength) and Leverage Map (relative importance) — Action ROI is the worth-it call once friction is priced in.

Action ROI score

32/100 Poor ROI Trust grade D

No. Every headline claim rests on a single tiny unreplicated trial, a blood marker that never reached a real outcome, or a rodent study. Your diet already covers it.

Time

Low

Money

Low

Effort

Low

Risk

Low

Why this score

Trust is grade D and the main story: the testosterone, osteoarthritis, and period-pain claims each rest on a single small unreplicated trial (Naghii 2011, N=8 open-label, 7 days; Newnham 1994, N=20; Nikkhah 2015), and the most-cited weight-loss meta-analysis (Farrin 2022) explicitly excluded humans.
Benefit in healthy adults is unproven across the board: the bone claim is only reduced urinary calcium and magnesium loss (Meacham 1994), a blood marker that never reached a fracture or bone-density outcome.
Time and effort are trivial (a daily capsule), which does not rescue a product with no demonstrated benefit.
Money looks cheap at $4 to $8 a month for boric acid, but consumers are routinely upsold to $15 to $30 calcium fructoborate with no head-to-head proof it absorbs or works better.
Risk is genuinely low at sensible doses, which is the only thing keeping this out of the basement, but low risk plus no benefit still equals poor value, and the upper limit (10mg/day EFSA) leaves little room.

Why it didn’t score higher

The headline reasons people buy it (testosterone, weight loss, cognition, bone) are each unsupported in healthy adults.
A normal Western diet already supplies 1 to 2mg/day, covering everything the human evidence actually demonstrates, so a capsule replaces food that was already adequate.
The premium forms are a marketing markup with no pharmacokinetic head-to-head behind them.

Best for

Realistically no one chasing the marketed benefits; the documented biological roles are covered by eating fruit, nuts, legumes, and coffee
Women with primary dysmenorrhea willing to trial it on single-RCT, direction-only evidence (10mg/day for 2 cycles, Nikkhah 2015)
Adults with osteoarthritis who have exhausted evidence-grade options, on single-pilot evidence (6mg/day for 8 weeks, Newnham 1994), accepting it is not in major OA guidelines

Lower ROI if

You are a eugonadal man expecting a testosterone boost (the claim is one N=8 open-label 7-day study)
You are seeking weight loss (the cited meta-analysis excluded humans)
You are a postmenopausal woman seeking fracture prevention (biomarker-only signal, no fracture or BMD trial exists)
You are paying premium for calcium fructoborate, boron glycinate, or amino acid chelate

Minimum effective dose

None justified for healthy adults; diet (fruit, nuts, coffee, legumes) covers the 1 to 2mg/day the evidence supports. If trialing a narrow indication, plain boric acid 6mg/day for 8 weeks (osteoarthritis) or 10mg/day for 2 cycles (dysmenorrhea), staying below the 10mg/day EFSA upper limit, with modest expectations.

Track this

Nothing reliable to track for the marketed claims, since none have a demonstrated human outcome
If trialing for OA or period pain, your own symptom score at 8 to 12 weeks, then stop if no clear change